Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2

References

• Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 2015;121:269–75.
   PubMed Web of Science ®Google Scholar
• Moran A, O’Hara C, Khan S, Shack L, Woodward E, Maher ER, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer 2012;11:235–42.
   PubMed Web of Science ®Google Scholar
• Mocci E, Milne RL, Mendez-Villamil EY, Hopper JL, John EM, Andrulis IL, et al. Risk of pancreatic cancer in breast cancer families from the breast cancer family registry. Cancer Epidemiol Biomarkers Prev 2013;22:803–11.
   PubMed Web of Science ®Google Scholar
• Noh JM, Choi DH, Baek H, Nam SJ, Lee JE, Kim JW, et al. Associations between BRCA mutations in high-risk breast cancer patients and familial cancers other than breast or ovary. J Breast Cancer 2012;15:283–7.
   PubMed Web of Science ®Google Scholar
• Mai PL, Chatterjee N, Hartge P, Tucker M, Brody L, Struewing JP, et al. Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, pancreatic cancers and melanoma. PLoS One 2009;4:e4812.
   PubMed Web of Science ®Google Scholar
• Sanz J, Ramón y Cajal T, Torres A, Darder E, Gadea N, Velasco A, et al. Uptake of predictive testing among relatives of BRCA1 and BRCA2 families: A multicenter study in northeastern Spain. Fam Cancer 2010;9:297–304.
   PubMed Web of Science ®Google Scholar
• Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men. Cancer 2004; 101:51–7.
   PubMed Web of Science ®Google Scholar
• Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 2013;24:1434–43.
   PubMed Web of Science ®Google Scholar
• Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:1811–4.
   PubMed Web of Science ®Google Scholar
• Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310–6.
   PubMed Web of Science ®Google Scholar
• Thompson D, Easton D, Breast Cancer Linkage Consortium. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410–9.
   PubMed Web of Science ®Google Scholar
• Easton DF, Steele L, Fields P, Ormiston W, Averill D, Daly PA, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997;61:120–8.
   PubMed Web of Science ®Google Scholar
• Evans DGR, Susnerwala I, Dawson J, Woodward E, Maher ER, Lalloo F. Risk of breast cancer in male BRCA2 carriers. J Med Genet 2010;47:710–1.
   PubMed Web of Science ®Google Scholar
• Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003;72:1–12.
   PubMed Web of Science ®Google Scholar
• Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 2011;105:1230–4.
   PubMed Web of Science ®Google Scholar
• Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer 2012;106:1697–701.
   PubMed Web of Science ®Google Scholar
• Thompson D. Cancer incidence in BRCA1 mutation carriers. Cancer Spectrum Knowl Environ 2002;94:1358–65.
   Web of Science ®Google Scholar
• Consortium TBCL. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310–6.
   PubMed Web of Science ®Google Scholar
• Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997;15:103–5.
   PubMed Web of Science ®Google Scholar
• Deb S, Jene N, Kconfab investigators, Fox SB. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. BMC Cancer 2012; 12:510.
   PubMed Web of Science ®Google Scholar
• Edwards SM, Evans DGR, Hope Q, Norman AR, Barbachano Y, Bullock S, et al. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 2010;103:918–24.
   PubMed Web of Science ®Google Scholar
• Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010;16:2115–21.
   PubMed Web of Science ®Google Scholar
• Tryggvadóttir L, Vidarsdóttir L, Thorgeirsson T, Jonasson JG, Olafsdóttir EJ, Olafsdóttir GH, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:929–35.
   PubMed Web of Science ®Google Scholar
• Thorne H, Willems AJ, Niedermayr E, Hoh IMY, Li J, Clouston D, et al. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev Res 2011;4:1002–10.
   PubMed Web of Science ®Google Scholar
• Castro E, Goh CL, Eeles RA. Prostate cancer screening in BRCA and Lynch syndrome mutation carriers. Am Soc Clin Oncol Educ Book 2013;33:e50.
   Google Scholar
• Akbari MR, Wallis CJD, Toi A, Trachtenberg J, Sun P, Narod SA, et al. The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer. Br J Cancer 2014;111:1238–40.
   PubMed Web of Science ®Google Scholar
• Edwards SM, Evans DGR, Hope Q, Norman AR, Barbachano Y, Bullock S, et al. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 2010;103:918–24.
   PubMed Web of Science ®Google Scholar
• Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl 2012;14:409–14.
   PubMed Web of Science ®Google Scholar
• Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: Results from the initial screening round of the IMPACT study. Eur Urol 2014;66:489–99.
   PubMed Web of Science ®Google Scholar
• Lubinski J, Phelan CM, Ghadirian P, Lynch HT, Garber J, Weber B, et al. Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer 2004;3:1–10.
   PubMedGoogle Scholar
• Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68:700–10.
   PubMed Web of Science ®Google Scholar